NervGen Pharma Corp. NGEN.V

NGEN.V Company Overview

NervGen Pharma Corp. is a clinical-stage biotechnology company focused on developing therapies to promote nervous system repair and functional recovery following damage to the central and peripheral nervous systems. The company operates in the biopharmaceutical industry, with a primary emphasis on neurology and regenerative medicine. NervGen’s lead product candidate is NVG-291, a peptide-based therapeutic designed to target inhibitory mechanisms that limit nerve regeneration after injury or disease. The company’s research is based on discoveries originating from work conducted at Case Western Reserve University, particularly involving mechanisms associated with chondroitin sulfate proteoglycans (CSPGs), which are known to inhibit neural repair.

The company’s principal strategic focus is the development of treatments for spinal cord injury, multiple sclerosis, stroke, and other neurological conditions where nerve regeneration and neuroplasticity are clinically important. NervGen positions itself within a specialized segment of the biotechnology market centered on neurorepair rather than symptomatic management alone. The company was founded in 2017 and is headquartered in Vancouver, Canada. Since inception, it has evolved from a preclinical neuroscience platform into a clinical-stage biotechnology company advancing human trials and translational neuroscience programs.